a member of the arrestin/beta-arrestin protein family. These proteins participate in agonist-mediated desensitization of G-protein-coupled receptors. Acts as a cofactor in the beta-adrenergic receptor kinase (BARK) mediated desensitization of beta-adrenergic receptors. Expressed at high levels in the CNS and peripheral blood leukocytes. Note: This description may include information from UniProtKB.
Molecular Function: angiotensin receptor binding; protein kinase B binding; protein binding; G-protein-coupled receptor binding; ubiquitin protein ligase binding; protein complex scaffold; receptor binding
Biological Process: arrestin mediated desensitization of G-protein coupled receptor protein signaling pathway; transcription from RNA polymerase II promoter; platelet activation; proteasomal ubiquitin-dependent protein catabolic process; regulation of protein amino acid phosphorylation; negative regulation of interleukin-12 production; Notch signaling pathway; negative regulation of natural killer cell mediated cytotoxicity; positive regulation of synaptic transmission, dopaminergic; protein ubiquitination; negative regulation of interleukin-1 beta production; negative regulation of tumor necrosis factor production; adult walking behavior; positive regulation of protein kinase B signaling cascade; protein transport; G-protein coupled receptor internalization; inhibition of NF-kappaB transcription factor; positive regulation of protein ubiquitination; receptor internalization; transforming growth factor beta receptor signaling pathway; negative regulation of interleukin-6 production; negative regulation of toll-like receptor signaling pathway; negative regulation of protein ubiquitination; blood coagulation
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.